Ask AI
ProCE Banner Activity

Shifting the Paradigm in B-Cell ALL: Insights on the Evolving Role of Bispecific Antibodies and CAR T-Cell Strategies

Clinical Thought

Gain insights on recent findings related to the use of bispecific antibodies and CAR T-cell therapy for patients with ALL including new data with blinatumomab, the novel bispecific antibodies surovatamig and CN201 engineered for improved characteristics, and optimizing the implementation of brexu-cel and obe-cel therapy.

Released: August 08, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Faculty Disclosure

Primary Author

Ibrahim Aldoss, MD: consultant/advisor/speaker: AbbVie, Adaptive, Amgen, Autolus, Jazz, Kite, MacroGenics, Pfizer, Syndax, Takeda, Wugen.

Jae H. Park, MD: consultant/advisor/speaker: Adaptive Technologies, AffyImmune, Allogene, Amgen, Artiva Biotherapeutics, Autolus, Be Biopharma, BeiGene, Bright Pharmaceuticals, Bristol Myers Squibb, Caribou Biosciences, Curocell, Galapagos, IN8Bio, Kite, Kura Oncology, Minerva, Novartis, Pfizer, Servier, Synthekine, Takeda.